The EDC is live today — see what ships now
All studies
NCT06735833From ClinicalTrials.govRecruiting

MMA Embolization for Refractory Chronic Migraine

Feasibility Study to Evaluate the Initial Safety and Effectiveness of TRUFILL n-BCA Liquid Embolic System in Middle Meningeal Artery Embolization for the Preventive Treatment of Refractory Chronic Migraine

  • Migraine Disorders

At a glance

Phase
Phase not stated
Study type
Interventional
Sponsor
Cerenovus, Part of DePuy Synthes Products, Inc.
Enrolment target
70
Started
23 April 2025
Main results due
25 December 2026
Study sites
8
Registry updated
25 September 2026

Can you take part?

  • Ages 18 years to 65 years.
  • Open to any sex.
  • You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria
Participant Inclusion Criteria, Candidates for this study must meet ALL the following inclusion criteria:

1. Patient is between 18 and 65 years of age (inclusive) at the time of consent
2. Age of onset of Chronic Migraine \<= 64 years
3. Age of onset of migraine diagnosis \< 50 years
4. Patient has a current diagnosis of refractory migraine
5. Patient has a current diagnosis of Chronic migraine

Participant Exclusion Criteria, Candidates will be excluded from participation if ANY of the following apply:

1. Patients with a history for the last 2 years of other primary headache types, or secondary headache types except medication overuse headache
2. Patients with diagnosis of hemiplegic migraine or migrainous infarct
3. Patients with current regular use of Opioids, Cannabis, Medical Marijuana, etc
4. Women who are pregnant, lactating, or who are of childbearing age
5. Current involvement in an investigational (drug, device, etc.) clinical trial that may confound study endpoints. Participants in observational, natural history, and/or epidemiological studies not involving intervention are eligible. Sponsor approval is required

What this study is about

In the sponsor’s own words, from the registry.

This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.

Study sites(8)

  • John Muir Physician Network Clin. Research Center

    Walnut Creek, California, United States

    Recruiting

  • Hartford Hospital

    Hartford, Connecticut, United States

    Recruiting

  • University of Buffalo Medical Center

    Buffalo, New York, United States

    Recruiting

  • Mount Sinai

    New York, New York, United States

    Recruiting

  • Stony Brook University Medical Center

    Stony Brook, New York, United States

    Recruiting

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, United States

    Recruiting

  • Semmes Murphey Foundation

    Memphis, Tennessee, United States

    Recruiting

  • West Virginia University

    Morgantown, West Virginia, United States

    Recruiting

Showing 8 of 8 sites. 8 of the 8 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT06735833. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me
MMA Embolization for Refractory Chronic Migraine | Trialion